Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Fotolyn (Pralatrexate) Chemotherapy Beats Tarceva on Survival as Second Line Therapy in Smokers

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

It's been two and a half years since I described a phase IIB trial of Fotolyn (pralatrexate), a relatively new chemotherapy agent, being compared to Tarceva (erlotinib) in current or ex-smokers with previously treated advanced NSCLC. The new drug, Fotolyn, is described in a prior post, and it has since been approved by the FDA as a treatment for peripheral T-cell lymphomas, so it's commercially available in the US. Today, Allos Therapeutics, the company that makes Fotolyn, sent out a press release that the clinical trial is positive for a modest survival advantage vs. Tarceva in this trial of current and former smokers. A total of 201 patients were enrolled, with a 13% improvement in OS in the overall population (166 included for analysis). In addition, there were some predefined patient groups for subset analysis, which demonstrated that light smokers (I don't have the precise definitions for light vs. heavy smoking history) did particularly better with Fotolyn (HR 0.63, corresponding to a 37% improvement), as did patients with non-squamous cancers (HR 0.65, corresponding to a 35% improvement). They saw trends in favor of Fotolyn for overall survival in all groups except those with squamous NSCLC and those who received prior Alimta (pemetrexed).

The other side of the coin is drug safety, which showed that mucositis (mouth sores) were moderate to severe in 23% of patients, and other common but typically relatively mild side effects included decreased blood counts (expected with just about all standard chemo agents), fatigue, and shortness of breath (which may have been more from the underlying cancer). These results are certainly interesting and fairly promising. We would expect that Tarceva's benefit is not very strong in current smokers or those with a significant smoking history, but Fotolyn didn't beat Tarceva in heavy smokers, nor was it convincingly better in patients with squamous NSCLC, a group that we think of as receiving pretty minimal to modest benefit with Tarceva. It's also not clear whether there is anything to the subset analysis that showed no benefit of Fotolyn over Tarceva in patients who received prior Alimta. This wasn't a large trial, and subset analyses, especially in small trials, can sometimes randomly show differences that aren't really real, or miss differences that actually exist, because small sample groups are unreliable. I presume that Allos will pursue in moving Fotolyn forward in NSCLC, in terms of getting FDA approval; this randomized phase IIB trial, very much designed like an underpowered phase III trial, is ostensibly enough to move forward with a larger trial that can lead to FDA approval. The lack of mention of P values in the press release leads me to presume that differences are not significant, but I'm sure we'll learn more once the results of this trial are presented in an upcoming meeting. In the meantime, it's possible that this will lead to some use of Fotolyn in NSCLC patients, at least those with a smoking history, but I expect that getting it covered by insurance may be challenging until we have more data. At the very least, this is a promising lead as a new option to hope to see for current or previously smoking patients with previously treated advanced NSCLC.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
Article
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 

Forum Discussions

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Hi Oaktowngrrl,  Welcome to Grace.  I'm so sorry you're going through this.

 

 Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...

Recent Comments

JOIN THE CONVERSATION
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on
Hi Blaze,

 

As much as I…
By JanineT GRACE … on